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Abstract  
Objective 
Moderate to severe chronic pain affects one in five adults. Pain may increase the risk of 
mortality but the relationship is unclear. This study investigated whether mortality risk was 
influenced by pain phenotype, characterised by pain extent or pain impact on daily life. 
Methods 
The study population was drawn from two large population cohorts of adults aged ≥50 
years; the English Longitudinal Study of Ageing (ELSA) (n=6324) and the North Staffordshire 
Osteoarthritis Project (NorStOP) (n=10985). Survival analyses (Cox’s proportional hazard 
models) estimated the risk of mortality in participants reporting “any pain” and then 
separately according to the extent of pain (total number of pain sites; widespread pain 
according to American College of Rheumatology (ACR) criteria; widespread pain according 
to Manchester criteria) and pain impact on daily life (pain interference; and often troubled 
with pain). Models were cumulatively adjusted for age, sex, education and wealth/adequacy 
of income. 
Results 
After adjustments, the report of any pain (MRR 1.06, 95% CI (0.95, 1.19)) or having 
widespread pain (ACR 1.07 (0.92, 1.23) or Manchester 1.16 (0.99, 1.36)) was not associated 
with an increased risk of mortality. Participants who were often troubled with pain (1.29 
(1.12, 1.49)) and those that reported “quite a bit” (1.38 (1.20,1.59)) and “extreme” (1.88 
(1.54, 2.29)) pain interference had an increased risk of all-cause mortality.  
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Conclusion 
Pain that interferes with daily life, rather than pain per se was associated with an increased 
risk of mortality. Future studies should investigate the mechanisms through which pain 
increases mortality risk. 
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Significance and Innovations 
 Pain impact is key to understanding the relationship between pain and mortality. 
 An investigation of potential mechanisms of a relationship between pain and 
mortality is warranted. 
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Pain has a major impact on individuals and society (1), is acknowledged by the World Health 
Organisation and the United Nations as a global problem, and is increasingly recognised as a 
condition in its own right (2). A significant proportion of people in the general population 
develop persistent disabling pain, and this contributes to the high number of years lost to 
disability attributed to painful conditions (3). However, pain may also carry an increased risk 
of mortality, although the risk is unclear and the evidence contradictory (4,5).  Some of the 
risk may be attributed to underlying disease such as cancer, which is considered to cause 
the pain [3], but the important question of whether the experience or nature of chronic pain 
confers a risk of premature death is unresolved  (6,4,7,8,5,9–13).  
A recent systematic review and meta-analysis of the relationship between chronic pain and 
mortality (14) indicated a modest but non-significant risk of mortality for people with pain, 
but with high heterogeneity between studies. An important source of variability was 
differences in pain phenotype between studies, with heterogeneous definitions of pain 
defined on the basis of pain extent (number of locations), duration and impact. Previous 
studies have suggested that mortality risk may be influenced by pain extent and duration  
(8,15). For example, strong associations have been reported between chronic widespread 
pain and mortality (MRR 2.8; 95%CI 1.3,6.1)  (9); and people with fibromyalgia who satisfied 
the more stringent American College of Rheumatology (ACR) 2010 criteria had an increased 
risk of mortality when compared to those satisfying the less stringent 1990 criteria only (HR 
1.62; 95%CI 1.19, 2.21) (11,16). 
The aim of this study was to investigate the effect of pain phenotype on the association 
between pain and mortality in older adults, using two different population cohorts, and to 
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test the hypothesis that the association with mortality increases with increasing pain extent 
and impact on daily life.   
Materials and Methods  
Design Overview, Setting and participants 
Two population based cohort studies of older adults were used in this study: the English 
Longitudinal Study of Ageing (ELSA) (17) and the North Staffordshire Osteoarthritis Project 
(NorStOP). The data collection methods for these studies are described in detail elsewhere  
(18,19). Briefly, ELSA is a large scale longitudinal panel study of the health, economic and 
social circumstances of adults aged 50 years and over in England which began in 2002. 
NorStOP is a cohort study designed to assess the prevalence and impact of pain in a 
community sample of adults aged 50 years and over in North Staffordshire, England. 
NorStOP also began in 2002. Pain and putative confounders were identified using data from 
wave 2 (collected in 2004) of ELSA and the NorStOP baseline samples (collected during 2002 
to 2005). A total of 6324 (67%) of participants in the ELSA and 10985 (59%) of the NorStOP 
study participants had complete predictor, outcome, and putative confounders data 
(including characteristics tested as mediators in a subsequent study) and were used in this 
analysis. (Figures i and ii in the supplementary material display how these samples were 
derived). 
 
Pain phenotypes (see Table i in supplementary material for details) 
Often troubled 
Participants in the ELSA were asked whether they were often troubled with pain. Those 
replying “yes” were classified as being often troubled with pain. 
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Severity 
Participants who were classified as being often troubled with pain were then asked to rate 
the severity of their pain as mild, moderate, or severe. 
Any pain 
Participants in the NorStOP study were asked “In the past 4 weeks have you had pain that 
has lasted for one day or longer in any part of your body (not including pain from illnesses 
such as flu)?” Those participants who responded “Yes” were categorised as having “any 
pain”. 
Widespread pain (ACR criteria) 
Participants in the NorStOP study classified as having “any pain” were then asked to shade 
the site of their pain on a blank body manikin (front and back views). Based on their pain 
reports those satisfying the ACR criteria for widespread pain (pain in the axial skeleton, on 
the right and left sides of the body and above and below the waist) (20) were identified. 
Widespread pain (Manchester criteria) 
Participants in the NorStOP study who satisfied the Manchester criteria for widespread pain 
(pain in both the axial skeleton and at least two sections of two contralateral limbs) (21) 
were also identified. 
Number of pain sites 
In addition, for participants in the NorStOP study the number of shaded areas on the body 
manikin (one to 44) was calculated and categorised into quartiles of 1-3 sites, 4-6 sites, 7-11 
sites and 12+ sites of pain. 
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Pain interference 
Participants in the NorStOP study were asked to complete the Medical Outcomes Study 
(MOS) Short Form (SF)-12 (22) . The MOS SF12 includes the question “During the past 4 
weeks how much did pain interfere with your normal work (including both work outside the 
home and housework)?” (‘Extremely’, ‘Quite a bit’, ‘Moderately’, ‘A little bit’, ‘Not at all’).  
Vital status 
Vital status for the ELSA sample was obtained from the Office of National Statistics (ONS) 
and for the NorStOP sample from the patient registration system held at the local Primary 
Care Trust and from dates of death notified to the NorStOP project team. These latter dates 
of death were confirmed using manual tracing of the NHS Summary Care Record 
Demographic system. 
 
The statistical analysis used Cox’s proportional hazard modelling to assess the risk of death 
according to pain phenotype (see below for details). In order to calculate hazard ratios, it 
was necessary to determine the length of time until the event (death) or censoring took 
place. 
 
For participants in the ELSA, information on year of death was available until the end of 
February 2012; time in the study was calculated in months from the date of interview until 
the 31st December in the year the participant was known to have died (or 28th February if 
they died in 2012). The censor date for those who survived was the 28th February 2012. 
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For participants in the NorStOP study, the number of days participants remained in the 
study from the date of questionnaire completion to the date of death or censoring was 
used. Information on vital status was available until 1st October 2012.  
 
Putative confounders 
Demographic variables were age, sex and socio-economic status indicated by educational 
attainment and current wealth (ELSA)/adequacy of income (NorStOP). These were 
considered to be the major potential confounders of the mortality-phenotype link according 
to the analytic strategy used in this study. In both datasets age was categorised into year 
bands 50-59, 60-69, 70-79 and 80 and over. 
 
For educational attainment, in ELSA participants were asked to look at a card listing 
educational qualifications and indicate which, if any, they held; participants were 
categorised to the highest qualification they held (National Vocational Qualification 
(NVQ)4/5 or degree or equivalent, higher education (university) below degree, 
NVQ3/Advanced level equivalent, NVQ2/Ordinary level equivalent, NVQ1/Certificate of 
Secondary (high school) education (CSE) or equivalent or foreign/other or no qualification). 
In NorStOP educational attainment was assessed by asking participants to indicate whether 
they had continued full-time education beyond school (response options ‘yes/no’) which 
formed a dichotomous variable indicating school education/further education. 
For wealth, in ELSA net total non-pension wealth, was categorised by using quintiles to 
provide five groups labelled from low to high. This measure of wealth has been found to be 
the strongest socioeconomic predictor of health in the ELSA sample  (23). In NorStOP, 
perceived adequacy of income was measured with a single item. Participants were asked to 
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compare the adequacy of their income with their living costs and indicate their situation 
(find it a strain to get by from week to week/ have to be careful with money/ able to 
manage without much difficulty/ quite comfortably off). This item measures a range of 
financial circumstances (from affluence to poverty) without eliciting details of responders’ 
income and is robust indicator of financial capacity in older adults  (24). 
Statistical analysis 
A comparison between the study samples (ELSA n=6324, NorStOP 10985) and larger 
samples containing participants with only predictor, outcome and putative confounder 
information (ELSA n= 8572, NorStOP n=14023) i.e. those without complete data for the 
characteristics tested as mediators in a subsequent study (see figures i and ii in 
supplementary data for details) was undertaken to assess for potential selection bias. A 
weighted analysis (where weights were calculated using age, sex, education and 
wealth/income variables and applied to the study sample to estimate the effects in the 
larger sample) was also undertaken to assess for selection bias. The distribution of 
demographic and socioeconomic factors was examined by vital status in both samples. 
Cox’s proportional hazard modelling was used to assess the risk of death for each pain 
phenotype, using time to death as the outcome. First, univariate models were constructed 
to examine the association between each pain phenotype and mortality (Model 1). Then in 
multivariable models the association for each phenotype was cumulatively adjusted for age 
and sex (Model 2) and then education and wealth (ELSA)/adequacy of income (NorStOP) 
(Model 3). The assumption of proportionality for each of the survival models was tested 
using Schoenfeld tests and plots of Schoenfeld residuals. These assumptions were valid for 
“often troubled” with pain, pain severity, any pain, widespread pain (ACR and widespread 
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pain (Manchester criteria). For pain interference, Schoenfeld tests indicated the assumption 
of proportionality did not hold, and so the  period was divided into two periods in 
accordance with previous research  (25); the first  period ranged from 0-365 days (0-1 year) 
and the second  period was  >366 days (i.e. 2-10 years). The proportionality assumption was 
met for both of these periods. 
Stata version 13 was used for all analyses. The results of the Cox’s proportional hazard 
models are presented as Mortality Rate Ratios (MRRs) with 95% confidence intervals (CI).  
Results  
Sample characteristics 
ELSA 
There were 6324 participants included in the ELSA sample for the analysis of the 
relationship between mortality and often troubled with pain and pain severity. The median 
age of the sample was 63 years and 55% were female (Table ii supplementary data). Those 
with missing data were more likely to be troubled with pain, have greater severity of pain, 
be older, female, have lower levels of education and be financially poorer than those with 
complete data (Table ii supplementary data). 
The length of time in the study for those who died (n=764 (12.1%)) ranged from 0 months to 
90 months from the date of interview, with a mean survival time of 54.1 months (SD 24.7). 
Within 12 months of the interview date forty deaths (5.2%) occurred. The proportion of the 
sample reported being “often troubled” with pain was 35.9% with 6.5% reporting this to be 
of severe intensity (Table iii supplementary data). The proportion of the sample educated to 
degree level or above was 14.5%. Participants who died during 8 years of follow-up (n=764), 
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compared with those who remained alive (n=5560), were older, and more likely to be male, 
lower socioeconomic status (i.e. lower education and wealth), often troubled with pain, and 
reported greater severity of pain (Table iii supplementary data). 
NorStOP 
There were 10985 participants included in the NorStOP sample for the analysis of the 
relationship between mortality and any pain, widespread pain (ACR and Manchester 
criteria), number of pain sites and pain interference. The median age was 63 years and 54% 
of the sample were female.  
Participants with complete data were more likely to be younger, less likely to be female, be 
better educated, have greater adequacy of income, and report pain interference than those 
with missing data (Table iv supplementary data). 
The length of time in the study for participants who died (n=1484 (13.5%)) ranged from 7 
days to 3823 days from the date of response with a mean survival time of 2036 days (SD 
1052). Within 12 months from the date of response 6.5% (n=97) of deaths occurred.  The 
proportion of the sample reporting “any pain” was 71.2%, with 25.0% of the sample 
meeting the ACR criteria for widespread pain and 15.7% meeting the Manchester criteria for 
widespread pain (Table iv supplementary data). The proportion of the sample reporting pain 
at 12 anatomical sites or more was 18.8% and 5.5% of the sample reported extreme pain 
interference. Participants who died in the NorStOP sample were more likely to be older, 
male, of lower socioeconomic status (measured according to education and income), and 
more likely to report pain interference. There were no differences in the report of any pain, 
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ACR WP, Manchester WP, and number of pain sites between those who died and those who 
remained alive (Table v supplementary data). 
An exploration of the relationship between the number of pain sites and pain interference 
variable used in this study was undertaken (Table 1). The highest proportion of deaths 
occurred for those reporting only 1-3 sites of pain but extreme pain interference (37.5%). 
The relationship between pain phenotypes and mortality 
Often troubled with pain (ELSA cohort) 
The rate of mortality was higher in those often troubled with pain when compared to those 
not often troubled with pain (Figure iii supplementary data) and this remained significant 
when adjusted putative confounders (Table 2). 
Pain severity (ELSA cohort) 
When compared to those reporting they were not “often troubled” with pain, participants 
who reported being often troubled with mild pain were no more likely to die over the follow 
up period, but participants reporting being often troubled by moderate or severe pain had 
increased mortality risks. These latter two estimates attenuated but remained significant 
when adjusted for age and sex (Model 2) and for age, sex, education and wealth (Model 3). 
The weighted analysis had little effect on the results (Table 2). 
Any pain (NorStOP cohort) 
Visually, the mortality rate was higher across the study period for those with “any pain” 
compared to those with no pain (Figure iv supplementary data). However, there was no 
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statistically significant increased risk of mortality for participants with “any pain” (Model 1) 
with no change when adjusted for potential confounders (Models 2 and 3) (Table 3).   
Widespread pain (ACR criteria) (NorStOP cohort) 
There was no association between mortality and widespread pain by the ACR criteria or for 
widespread pain that did not meet the ACR criteria (Table 3).  
Widespread pain (Manchester criteria) (NorStOP cohort) 
For participants with widespread pain that met the Manchester criteria there was an 
increased risk of mortality in the analyses adjusted for age and sex only. There was no 
increased risk of mortality for pain that did not meet the Manchester criteria for widespread 
pain (Table 3). 
Number of pain sites (NorStOP cohort) 
There was a significant increased risk of mortality for participants with 12 or more pain sites 
adjusted for age and sex only. There was no trend of increased mortality risk with number of 
pain sites (Table 3). 
The weighted analysis for all of the above phenotypes had little effect (Table 3). 
Pain interference (NorStOP cohort)  
Pain interference was associated with increased mortality over time (Figure v 
supplementary data). The risk of mortality associated with pain interference was higher in 
the first year of follow up than for the following 9 years (Tables 4 & 5). There were 97 
deaths in the first 12 months, with risk associated with increasing pain interference. “A 
little” and “moderate” pain interference were not associated with increased mortality; pain 
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that interfered “quite a bit” was associated in the crude model and when adjusted for age 
and sex, but this attenuated and became non-significant when adjusted for age, sex, 
education and adequacy of income. “Extreme” pain interference was associated with an 
increased risk of mortality in all models (Table 4).   
In the period 366 days to 10 years of follow up, there was no increased risk of mortality for 
participants with “a little” pain interference in the crude or adjusted models. For 
participants who indicated “moderate” pain interference there was an increased risk of 
mortality in the crude model only which attenuated and became non-significant when 
adjusted for confounders. Compared to those with no pain, participants reporting “quite a 
bit” or “extreme” pain interference had an increased risk of mortality in all models (Table 5). 
A weighted analysis was not repeated for the pain interference phenotype due to the need 
to split the analysis into time bands but from the previous results it is assumed this would 
have little effect.   
Discussion  
Summary of findings 
This study investigated the association between pain phenotype and mortality in two large 
population-based datasets. For the first time, we found the strongest association with 
mortality was a measure of the impact or troublesomeness of pain in daily life, consistent 
across both cohorts studied, whilst the presence of pain (yes/no) was not associated. 
Pain impact 
The magnitude of the relationship observed in the ELSA dataset between “troubling” pain 
and all-cause mortality (MRR 1.29; 95% CI 1.12, 1.49) was consistent with the association 
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between pain that interferes with daily life (to a moderate extent or more) and mortality in 
the NorStOP study. This consistency between the two cohorts adds to the credibility of this 
finding. 
By contrast with some previous findings from the literature, measures of the presence and 
extent of pain were not consistently associated with mortality risk. The phenotypes of pain 
extent tested in the NorStOP sample were comparable to phenotypes used in other studies  
(4,7), but the results did not confirm those studies. Macfarlane et al., 2001 used the ACR 
criteria to categorise widespread pain and found a 30% increased risk of mortality among 
those meeting the criteria after adjusting for age, sex and study location (4), confirmed in a 
later study by McBeth et al., (2009) that additionally adjusted for ethnic group and 
Townsend score of deprivation  (7). However, in the current study, participants meeting the 
ACR criteria for widespread pain did not have an increased risk of mortality.  
The findings from the NorStOP sample regarding the number of pain sites were unexpected 
as associations between increasing number of pain sites and a reduction in overall health, 
sleep quality, psychological health and decreased function (26) and increased mortality  (7) 
have been reported. In the current study, the highest proportion of deaths occurred for 
those reporting only 1-3 sites of pain but extreme pain interference (37.5%) (Table 1). 
Although there were only a small number of participants in this category, the finding does 
suggest that the link is with impact rather than with pain and pain extent per se. There is 
some correlation between a greater number of pain sites and the extent of pain 
interference (Table 1), but in the multivariable models it is pain interference, and not 
number of pain sites, that is independently associated with increased mortality in this study.  
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We conclude that the presence and extent of pain is not related to mortality but the impact 
that pain has on an individual’s daily life is.  
Strengths and limitations  
Pain prevalence 
Although there were some contrasts in the findings from the phenotypes in the NorStOP 
sample compared to previous studies, the pain phenotype data in NorStOP was collected 
using a validated approach and found in previous analyses to be reliable  (27). Our 
prevalence estimates for pain and widespread pain in the NorStoP sample are higher than 
those reported in previous UK population-based studies such as Macfarlane et al., (2001) 
and the McBeth et al., (2009) likely due to the sample being restricted to adults aged 50 
years and over.  
Methodological considerations 
Sample structure  
It was not possible to test all of the pain phenotypes within the same dataset. Differences in 
the structure of the study population may have influenced the observed relationships 
between pain phenotype and mortality. ELSA samples are generated with the intention of 
being representative of the English population of adults aged 50 years and over. In contrast 
the NorStOP dataset is sampled from a small number (n=8) of general practices in North 
Staffordshire and is less likely to be nationally representative. However, the age and sex 
structure of the participating NorStOP population is similar to that of North Staffordshire 
and to England and Wales  (28). Investigation of the age and sex distribution of the samples 
used for this study revealed that the ELSA and NorStOP samples had similar structures to 
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each other. Although selective samples were used and some differences in demographic 
and socioeconomic characteristics between those with and without missing data were 
indicated, there was sufficient power to detect the expected effect sizes (based on previous 
literature) and a weighted analysis indicated the missing data did not introduce bias to the 
results.  
Identification of vital status 
Vital status in the ELSA sample was determined using records from the Office of National 
Statistics whereas in NorStOP information was collated from two sources, the Exeter Patient 
registration system held at the local Primary Care Trust and through manual tracing of the 
NHS Summary Care Record Demographic system. Misclassifications may have occurred 
resulting in an under or over estimation of the true relationship between pain and mortality. 
However, the United Kingdom is considered to have high quality death registration data  
(29) so any inaccuracies should be minimal.  
Mortality information 
Only year of death information was available from the ELSA dataset for this study. This has 
implications for the accuracy of the observed MRRs. For participants who died, the time in 
the study was calculated from their date of interview until 31st December in the year the 
participant was known to have died. The actual date of death may have been earlier 
meaning survival time was overestimated and mortality risk was underestimated for ELSA 
participants in the current study.  
Pain phenotype 
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The current study used data obtained from two large population-based surveys with high 
response rates and it was possible to investigate the relationship between a number of 
different pain phenotypes and mortality. However, it was not possible to determine pain 
that was chronic (i.e. lasting for three months or more) in either dataset but this is unlikely 
to have affected the results as 80-90% of widespread pain is chronic  (4). Pain was measured 
at one point in time only and it is possible participants may have been misclassified or 
changed pain state over the follow-up period. This would result in an inaccurate 
representation of the relationship between pain and mortality (either an under or over-
estimation) but the number of misclassifications of pain state is likely to be small, resulting 
in minimal effect on the overall findings. 
Bias 
It is possible that early deaths resulted from causes (such as cancer) that pre-dated the 
onset of pain, and this might have dominated our findings. Our analysis of pain interference, 
because it separated mortality in the first year of follow-up from later deaths (tables 4 and 
5), provided an opportunity to examine this possibility. Although the point estimate of 
mortality risk was highest in the ‘extreme interference’ group in the first year, elevated risks 
of mortality after 12 months were seen for all grades of interference and were statistically 
more stable than those for year 1. This finding argues against any substantial influence of 
this form of bias.    
Implications for further research 
The findings from the current study demonstrated an increased risk of mortality for people 
who had pain that impacted on their life. A measure of pain impact along with measures of 
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presence and location would be a useful addition to any future studies of pain and 
mortality.  One of the research implications that follows from our study is the need to 
identify what it is about ‘interfering’ pain that causes premature mortality. Factors such as 
comorbid disease, lifestyle behaviours or psychological factors might provide links between 
pain that specifically disables or interferes with life and premature mortality. For example, 
pain that impacts on life is linked to a reduction in physical activity which is associated with 
increasing weight and the onset of health conditions (e.g. cardiovascular disease) that lead 
to mortality. Future analyses could usefully explore such pathways to identify targets for 
intervention to reduce the impact of pain on daily life and hence on premature mortality.    
Conclusion 
The impact of pain was more important than the presence or extent of pain in the 
relationship between pain and mortality. 
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Table 1. Cross tabulation of the number of pain sites and pain interference categories 
presenting the proportion of those who died in the NorStOP sample (n= 10953) *   
 % who died (Number of deaths/N) per cell 
No sites 1-3 sites 4-6 sites 7-11 sites 12+ sites Total 
No 
interference 
13.0% 
(412/3166) 
6.7% 
(46/683)  
6.9% 
(26/376) 
6.2% 
(12/195) 
4.0% 
(3/75) 
11.1% 
(499/4495) 
A little - 11.3% 
(81/714) 
10.1% 
(72/716) 
8.5% 
(48/565) 
7.9% 
(25/316) 
9.8% 
(226/2311) 
Moderately - 19.8% 
(59/298) 
17.2% 
(71/414) 
13.0% 
(57/440) 
11.4% 
(46/404) 
15.0% 
(233/1556) 
Quite a bit - 20.9% 
(47/225) 
24.5% 
(87/355) 
17.5% 
(89/510) 
15.9% 
(144/904) 
18.4% 
(367/1994) 
Extremely - 37.5% 
(12/32) 
24.7% 
(20/81) 
28.5% 
(35/123) 
23.8% 
(86/361) 
25.6% 
(153/597) 
Total 13.0% 
(412/3166) 
12.6% 
(245/1952) 
14.2% 
(276/1942) 
13.2% 
(241/1833) 
14.8% 
(304/2060
) 
13.5% 
(1478/10953) 
*excludes n=32 who indicated the presence of pain but did not indicate any pain sites on the pain manikin 
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Table 2.  Risk of all-cause mortality in the ELSA sample according to pain phenotype (n=6324) and weighted results  
Pain 
phenotype 
N Person years 
of follow up 
Number 
of deaths 
Mortality 
rate*  
Model 1 
MRR (95% 
CI) 
Model 2 
MRR (95% 
CI) 
Model 3 
MRR (95% 
CI) 
Weighted 
Model 1 
MRR 
 (95% CI) 
Weighted 
Model 2 
MRR  
(95% CI) 
Weighted 
Model 3 
MRR  
(95% CI) 
Not often 
troubled 
4052 28048 428 15.26 Reference Reference Reference Reference Reference Reference 
Often 
troubled  
2272 15414 336 21.80 1.43 (1.24, 
1.65) 
1.36 (1.18, 
1.58) 
1.29 (1.12, 
1.49) 
1.43 (1.24, 
1.65) 
1.37 (1.18, 
1.58) 
1.29 (1.11, 
1.50) 
Not often 
troubled 
4052 28048 428 15.26 Reference Reference Reference Reference Reference Reference 
Mild  680 4737 60 12.67 0.83 (0.63, 
1.09) 
0.87 (0.66, 
1.14) 
0.89 (0.68, 
1.16) 
0.82 (0.63, 
1.08) 
0.85 (0.65, 
1.12) 
0.87 (0.67, 
1.14) 
Moderate  1183 7943 201 25.31 1.65 (1.40, 
1.95) 
1.52 (1.28, 
1.80) 
1.42 (1.20, 
1.68) 
1.68 (1.42, 
1.98) 
1.54 (1.30, 
1.84) 
1.43 (1.20, 
1.72) 
Severe  409 2734 75 27.43 1.81 (1.41, 
2.31) 
1.70 (1.33, 
2.18) 
1.54 (1.20, 
1.97) 
1.80 (1.41, 
2.31) 
1.70 (1.31, 
2.19) 
1.53 (1.19, 
1.98) 
MRR=Mortality Rate Ratio, 95% CI = 95% confidence interval 
Model 1: Crude 
Model 2: Adjusted for age, sex  
Model 3: Adjusted for age, sex, education and wealth 
*per 1000 person-years 
MRRs in bold indicate significant associations 
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Table 3. Risk of all-cause mortality in the NorStOP sample according to pain phenotype (n=10985) and weighted results  
Pain 
phenotype 
N 
 
Person 
years of 
follow up 
Number 
of deaths 
Mortality 
rate*  
Model 1 
MRR  
(95% CI) 
Model 2 
MRR  
(95% CI) 
Model 3 
MRR  
(95% CI) 
Weighted 
Model 1 
MRR  
(95% CI) 
Weighted 
Model 2 
MRR  
(95% CI) 
Weighted 
Model 3 
MRR  
(95% CI) 
No pain  3166 28813 412 14.30 Reference Reference Reference Reference Reference Reference 
Any pain  7819 71116 1072 15.07 1.05 (0.94, 
1.18) 
1.08 (0.96, 
1.21) 
1.06 (0.95, 
1.19) 
1.00 (0.89, 
1.12) 
1.08 (0.96, 
1.20) 
1.06 (0.95, 
1.19) 
No pain 3166 28813 412 14.30 Reference Reference Reference Reference Reference Reference 
Pain but not 
ACR WP 
5038 45709 714 15.62 1.09 (0.97, 
1.23) 
1.06 (0.94, 
1.20) 
1.05 (0.93, 
1.19) 
1.06 (0.94, 
1.19) 
1.07 (0.95, 
1.20) 
1.06 (0.94, 
1.19) 
ACR WP 2749 25158 352 13.99 0.97 (0.85, 
1.12) 
1.10 (0.95, 
1.26) 
1.07 (0.92, 
1.23) 
0.90 (0.78, 
1.04) 
1.09 (0.95, 
1.26) 
1.07 (0.92, 
1.23) 
No pain 3166 28813 412 14.30 Reference Reference Reference Reference Reference Reference 
Pain but not 
Manchester 
WP 
6062 55194 827 14.98 1.05 (0.93, 
1.18) 
1.05 (0.93, 
1.18) 
1.03 (0.92, 
1.16) 
1.02 (0.90, 
1.14) 
1.05 (0.93, 
1.18) 
1.04 (0.92, 
1.17) 
Manchester 
WP 
1725 15673 239 15.25 1.06 (0.91, 
1.25) 
1.19 (1.02, 
1.40) 
1.16 (0.99, 
1.36) 
0.94 (0.80, 
1.11) 
1.19 (1.01, 
1.39) 
1.16 (0.99, 
1.36) 
No sites 3166 28813 412 14.30 Reference Reference Reference Reference Reference Reference 
1-3 sites 1952 17843 245 13.73 0.96 (0.82, 
1.12) 
0.95 (0.81, 
1.11) 
0.95 (0.81, 
1.11) 
0.95 (0.81, 
1.11) 
0.94 (0.81, 
1.10) 
0.94 (0.80, 
1.10) 
4-6 sites 1942 17559 276 15.72 1.10 (0.94, 
1.28) 
1.09 (0.94, 
1.27) 
1.08 (0.93, 
1.26) 
1.07 (0.92, 
1.24) 
1.09 (0.93, 
1.26) 
1.07 (0.92, 
1.25) 
7-11 sites 1833 16836 241 14.31 1.00 (0.85, 
1.17) 
1.07 (0.92, 
1.26) 
1.05 (0.90, 
1.24) 
0.94 (0.80, 
1.10) 
1.06 (0.91, 
1.25) 
1.05 (0.89, 
1.23) 
12+ sites 2060 18630 304 16.32 1.14 (0.98, 
1.32) 
1.18 (1.02, 
1.37) 
1.15 (0.99, 
1.34) 
1.01 (0.87, 
1.17) 
1.17 (1.01, 
1.36) 
1.14 (0.99, 
1.33) 
MRR= Mortality Rate Ratio, 95% CI = 95% confidence interval, ACR = American College of Rheumatology, WP = Widespread pain 
Model 1: Crude, Model 2: Adjusted for age, sex, Model 3: Adjusted for age, sex, education, adequacy of income 
*per 1000 person-years, MRRs in bold indicate significant associations 
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Table 4. Risk of all-cause mortality in the NorStOP sample according to pain interference in the first 
year of follow up (0-365 days) 
Pain 
interference 
N  
 
Person years of 
follow up 
Number of 
deaths 
Mortality 
rate*  
Model 1 MRR 
(95% CI) 
Model 2 MRR 
(95% CI) 
Model 3 MRR 
(95% CI) 
No interference 4501 4489 27 5.01 Reference Reference Reference 
A little 2316 2313 8 3.46 0.57 (0.26, 
1.27) 
0.61 (0.28, 
1.35) 
0.60 (0.27, 
1.32) 
Moderately 1562 1557 14 8.99 1.49 (0.78, 
2.85) 
1.31 (0.69, 
2.50) 
1.20 (0.63, 
2.30) 
Quite a bit 2004 1993 25 12.54 2.09 (1.21, 
3.59) 
1.78 (1.03, 
3.08) 
1.54 (0.88, 
2.68) 
Extremely 602 590 23 38.98 6.49 (3.72, 
11.33) 
5.49 (3.12, 
9.65) 
4.69 (2.64, 
8.34) 
MRR= Mortality Rate Ratio, 95% CI = 95% confidence interval 
Model 1: Unadjusted 
Model 2: Adjusted for age, sex  
Model 3: Adjusted for age, sex, education, adequacy of income 
*per 1000 person-years 
MRRs in bold indicate significant associations 
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Table 5. Risk of all-cause mortality in the NorStOP sample according to pain 
interference after the first year of follow up (365 to 3483 days) 
Pain 
interference 
N  
 
Person 
years of 
follow up 
Number 
of deaths 
Mortality 
rate*  
Model 1 
MRR (95% 
CI) 
Model 2 
MRR (95% 
CI) 
Model 3 
MRR (95% 
CI) 
No 
interference 
4474 41269 472 11.44 Reference Reference Reference 
A little 2308 21473 219 10.20 0.89 (0.76, 
1.04) 
0.94 (0.80, 
1.10) 
0.94 (0.80, 
1.10) 
Moderately 1548 14238 220 15.45 1.35 (1.15, 
1.58) 
1.13 (0.96, 
1.33) 
1.13 (0.96, 
1.32) 
Quite a bit 1979 17817 345 19.36 1.70 (1.48, 
1.95) 
1.39 (1.21, 
1.60) 
1.38 (1.20, 
1.59) 
Extremely 579 5078 131 25.80 2.27 (1.87, 
2.76) 
1.89 (1.55, 
2.30) 
1.88 (1.54, 
2.29) 
MRR= Mortality Rate Ratio, 95% CI = 95% confidence interval 
Model 1: Unadjusted 
Model 2: Adjusted for age, sex  
Model 3: Adjusted for age, sex, education, adequacy of income 
*per 1000 person-years 
MRRs in bold indicate significant associations 
 
